schizophrenia

News and resources

Apr 16 2026

Feasibility and Psychometrics of a New Test Battery for Diagnosing Patients With Schizophrenia Spectrum Disorders – Cureus

by Clinical Editor

No Comments

Feasibility and Psychometrics of a New Test Battery for Diagnosing Patients With Schizophrenia Spectrum Disorders Cureus

Apr 16 2026

Teva Launches Home Ground(TM) Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

by Clinical Editor

No Comments

For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground(TM) Schizophrenia Community is a centralized destination …

Apr 15 2026

Lybalvi Associated With Improvement in Negative Symptoms of Schizophrenia: Findings From Long-Term Analysis – Psychiatric Times

by Clinical Editor

No Comments

Lybalvi Associated With Improvement in Negative Symptoms of Schizophrenia: Findings From Long-Term Analysis Psychiatric Times

Apr 15 2026

Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry – BioSpace

by Clinical Editor

No Comments

Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry BioSpace

Apr 15 2026

Scientists Discover Why the Brain Gets Stuck in Schizophrenia – SciTechDaily

by Clinical Editor

No Comments

Scientists Discover Why the Brain Gets Stuck in Schizophrenia SciTechDaily

Apr 15 2026

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

by Clinical Editor

No Comments

For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground™ …

Apr 14 2026

Schizophrenia study tracks symptom gains for 56 weeks on LYBALVI – Stock Titan

by Clinical Editor

No Comments

Schizophrenia study tracks symptom gains for 56 weeks on LYBALVI Stock Titan

Apr 14 2026

Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry

by Clinical Editor

No Comments

Alkermes plc (Nasdaq: ALKS) today announced the publication of a 56-week post hoc analysis of the effects of LYBALVI® (olanzapine and samidorphan) on negative symptoms in adults living with …

Apr 13 2026

Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia

by Clinical Editor

No Comments

NBI-1117570 is an investigational oral, dual muscarinic M1/M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with …

Apr 11 2026

Boehringer and Click Announce CT-155 Funding and Investment – Boehringer Ingelheim

by Clinical Editor

No Comments

Boehringer and Click Announce CT-155 Funding and Investment Boehringer Ingelheim